# A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma

> **NCT05312411** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Osteosarcoma

## Interventions

- **BIOLOGICAL:** SCRI-E2CAR_EGFRtv1
- **DRUG:** UB_TT170

## Key facts

- **NCT ID:** NCT05312411
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-20
- **Primary completion:** 2025-03-12
- **Final completion:** 2040-05
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05312411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05312411, "A Phase I Feasibility And Safety Study of Fluorescein-Specific (FITC-E2) CAR T Cells In Combination With Parenterally Administered Folate-Fluorescein (UB-TT170) For Osteogenic Sarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05312411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*